Cardiology

More evidence evolocumab exceeds cost-effectiveness

(HealthDay)—At its current price, the addition of evolocumab to standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published ...

Cardiology

Cholesterol levels rise, fall with changing seasons

Cholesterol levels seem to fluctuate significantly with the turning seasons, which may leave some people with borderline high cholesterol at greater cardiovascular risk during the winter months, according to research being ...

Medical research

Biomarkers provide potential for better preeclampsia detection

Identifying biomarkers could lead to earlier detection of preeclampsia, which in turn can lead to healthier mothers and children, according to a collaborative study from the Centre of Molecular Inflammation Research (CEMIR) ...

page 22 from 26